| Literature DB >> 17351842 |
Jennifer S Haas1, Diana L Miglioretti, Berta Geller, Diana S M Buist, David E Nelson, Karla Kerlikowske, Patricia A Carney, Sarah Dash, Erica S Breslau, Rachel Ballard-Barbash.
Abstract
BACKGROUND: The news media facilitated the rapid dissemination of the findings from the estrogen plus progestin therapy arm of the Women's Health Initiative (EPT-WHI).Entities:
Mesh:
Year: 2007 PMID: 17351842 PMCID: PMC1824785 DOI: 10.1007/s11606-007-0122-7
Source DB: PubMed Journal: J Gen Intern Med ISSN: 0884-8734 Impact factor: 5.128
Demographic characteristics of 387,504 observations on 327,144 women from July 2001 to December 2002 and level of average potential exposure to newspaper articles with iInformation about the harmful effects of HT in July 2002
| Women | Average potential exposure during July 2002 (number of articles) | |||||
|---|---|---|---|---|---|---|
| <1.00 | 1.00–1.99 | 2.00–2.99 | 3.00+ | |||
| (Column %) | Row % | |||||
| Total observations | 327,144 | 54.8 | 17.4 | 15.0 | 12.8 | |
| Use of hormone therapy at baselinea: | ||||||
| No | 71,270 | 56.2 | 56.3 | 16.7 | 15.0 | 12.0 |
| Yes | 55,523 | 43.8 | 54.0 | 18.8 | 14.7 | 12.5 |
| Age (years) | ||||||
| 50–54 | 103,941 | 31.8 | 52.7 | 18.2 | 15.6 | 13.5 |
| 55–59 | 77,893 | 23.8 | 54.0 | 17.7 | 14.9 | 13.5 |
| 60–64 | 57,352 | 17.5 | 56.5 | 16.7 | 14.5 | 12.3 |
| 65–69 | 47,365 | 14.5 | 57.6 | 16.5 | 14.3 | 11.5 |
| 70–74 | 40,593 | 12.4 | 56.1 | 17.0 | 15.0 | 11.9 |
| Race/ethnicity | ||||||
| White, non Hispanic | 243,558 | 77.6 | 56.1 | 18.7 | 136 | 11.6 |
| Black, non Hispanic | 20,378 | 6.5 | 63.0 | 12.7 | 14.5 | 9.8 |
| Asian/Hawaiian/Pacific Islander | 16,845 | 5.4 | 11.4 | 4.8 | 36.7 | 47.1 |
| Other/Mixed (2+ races) | 6,407 | 2.0 | 60.8 | 13.2 | 12.0 | 14.0 |
| Hispanic | 26,797 | 8.5 | 69.1 | 10.1 | 13.7 | 7.0 |
| 1st degree family history of breast cancer* | ||||||
| No | 264,097 | 86.0 | 55.3 | 17.3 | 15.0 | 12.5 |
| Yes | 43,097 | 14.0 | 54.0 | 18.5 | 13.3 | 14.1 |
| Education* | ||||||
| <High school graduate | 27,232 | 10.4 | 64.0 | 10.7 | 14.7 | 10.6 |
| High school graduate | 72,295 | 27.6 | 63.9 | 16.7 | 11.5 | 7.9 |
| Some college or technical school | 71,491 | 27.3 | 50.4 | 18.6 | 15.9 | 15.1 |
| College graduate or postgraduate | 90,721 | 34.7 | 42.5 | 16.4 | 17.7 | 23.4 |
| Site* | ||||||
| North Carolina | 65.7 | 15.9 | 14.6 | 3.8 | ||
| New Hampshire | 44.8 | 40.2 | 12.3 | 2.6 | ||
| Vermont | 95.5 | 4.3 | 0.2 | 0.0 | ||
| San Francisco | 3.3 | 1.9 | 39.1 | 55.6 | ||
| Western Washington | 30.1 | 12.5 | 11.3 | 46.1 | ||
| New Mexico | 88.3 | 8.6 | 3.1 | 0.0 | ||
| Denver | 7.8 | 58.2 | 33.2 | 0.8 | ||
Characteristics of the women at the time of the first observation. Data were missing for: education (n = 13,159), family history (19,950), and education (65,405).
aBaseline period refers to July–December 2001.
*p < .001 for chi-square comparing level of average potential exposure across subgroups of women in each category.
Figure 1Hormone therapy prevalence by average potential exposure to newspaper coverage about the harmful effects of hormone therapy in July 2002. Each line represents the prevalence of hormone therapy (HT) use among women in each of the four groups that measure the average potential household exposure to newspaper coverage of the possible risks of HT during July 2002. The square line represents women who live in zip code with average potential exposure to <1.00 articles; the open-circle line represents women who live in a zip code with average potential exposure of 1.00–<2.00 articles; the star line represents women who live in a zip code with average potential exposure of 2.00–<3.00 articles; and the shaded-circle line represents women who live in a zip code with average potential exposure to at least three of these articles.
Adjusted relative risk of hormone therapy use after the publication of the EP-WHI results by level of average potential newspaper exposure relative to the lowest average potential exposure group
| Month (2002) | Level of average potential exposure to newspaper media in July 2002 | |||||
|---|---|---|---|---|---|---|
| 1.00–<2.00 | 2.00–<3.00 | 3.00+ | ||||
| August | 1.02 (0.97, 1.07) | .51 | 0.96 (0.91, 1.01) | .084 | 0.92 (0.87, 0.98) | .06 |
| September | 0.98 (0.93, 1.04) | .49 | 0.91 (0.85, 0.98) | .010 | 0.86 (0.79, 0.92) | <.0001 |
| October | 1.04 (0.98, 1.10) | .19 | 0.93 (0.86, 1.00) | .059 | 0.86 (0.80, 0.93) | <.0001 |
| November | 1.00 (0.94, 1.07) | .97 | 1.00 (0.92, 1.08) | .967 | 0.86 (0.80, 0.93) | <.0001 |
| December | 1.01 (0.93, 1.09) | .87 | 1.02 (0.93, 1.12) | .649 | 0.87 (0.80, 0.94) | .006 |
Model includes main effects of age, family history, race, and the baseline rate of hormone therapy use (defined as the average use between July and December 2001), and includes interactions of these variables with pre/post EP-WHI.
*p values compare each level of average potential exposure to referent group (exposed to <1 article in July 2002).